News
MSD data reveal undercuts eye drug remigromig's potential
In its decanting of the BRUNELLO trial of remigromig for diabetic macular oedema, MSD seems to have left observers contemplating a glass half empty.
News
Lilly's Zepbound enhances Taltz efficacy in psoriasis study
A study has shown that the efficacy of Lilly's psoriasis therapy Taltz is improved when it is given in combination with weight-loss drug Zepbound.
News
Iambic prices its IPO, seeking to raise up to $160m
AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
News
Matchpoint scores $150m for I&I drugs, and other financings
Matchpoint has closed a $150m round for its immunology-focused covalent drugs, with KymaThera, Rouge, Sensible Bio, and Arboretum also raising funds.
News
argenx's Forte acquisition delivers coeliac trial win
argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
